OBJECTIVE: Scripted video-vignette studies enable experimental investigation of specific elements of patient-provider communication, separating cause and effect. However, scripted video vignettes are infrequently used to this end. Resultantly, few guidelines are available for their design, development and administration. We aim to suggest guidelines enabling more informed decisions when designing and conducting these studies. METHODS: Based on the available methodological literature, we discuss methodological considerations when developing and administering scripted video vignettes. RESULTS: Developing and using valid video vignettes requires: (I) deciding if using video vignettes is appropriate, (II) developing a valid script, (III) designing valid manipulations, (IV) converting the scripted consultation to video, and (V) administering the videos. We provide a first checklist of the methodological considerations in each phase. Advantages and pitfalls of possible approaches are discussed. CONCLUSIONS: No 'gold standard' exists for most methodological issues, as literature testing the consequences of different approaches is lacking. The best approach when developing and implementing video vignettes depends upon the aims and practical limitations of a particular study. PRACTICE IMPLICATIONS: Our checklist may serve as a starting point for further study of scripted video vignettes methodology. More detailed methodological reporting would yield new knowledge, thus allowing the research field to progress.
OBJECTIVE: Scripted video-vignette studies enable experimental investigation of specific elements of patient-provider communication, separating cause and effect. However, scripted video vignettes are infrequently used to this end. Resultantly, few guidelines are available for their design, development and administration. We aim to suggest guidelines enabling more informed decisions when designing and conducting these studies. METHODS: Based on the available methodological literature, we discuss methodological considerations when developing and administering scripted video vignettes. RESULTS: Developing and using valid video vignettes requires: (I) deciding if using video vignettes is appropriate, (II) developing a valid script, (III) designing valid manipulations, (IV) converting the scripted consultation to video, and (V) administering the videos. We provide a first checklist of the methodological considerations in each phase. Advantages and pitfalls of possible approaches are discussed. CONCLUSIONS: No 'gold standard' exists for most methodological issues, as literature testing the consequences of different approaches is lacking. The best approach when developing and implementing video vignettes depends upon the aims and practical limitations of a particular study. PRACTICE IMPLICATIONS: Our checklist may serve as a starting point for further study of scripted video vignettes methodology. More detailed methodological reporting would yield new knowledge, thus allowing the research field to progress.
Authors: A T Chamberlain; R J Limaye; S T O'Leary; P M Frew; S E Brewer; C I Spina; M K Ellingson; M Z Dudley; W A Orenstein; M A Donnelly; L E Riley; K A Ault; D A Salmon; S B Omer Journal: Vaccine Date: 2019-04-05 Impact factor: 3.641
Authors: Niki M Medendorp; Marij A Hillen; Leonie N C Visser; Cora M Aalfs; Floor A M Duijkers; Klaartje van Engelen; Margreet G E M Ausems; Senno Verhoef; Anne M Stiggelbout; Ellen M A Smets Journal: Eur J Hum Genet Date: 2021-01-12 Impact factor: 5.351
Authors: Mariska de Wit; Bedra Horreh; Carel T J Hulshof; Haije Wind; Angela G E M de Boer Journal: Int Arch Occup Environ Health Date: 2022-01-13 Impact factor: 2.851
Authors: Jenni Burt; Gary Abel; Natasha Elmore; Cathy Lloyd; John Benson; Lara Sarson; Anna Carluccio; John Campbell; Marc N Elliott; Martin Roland Journal: BMJ Open Date: 2016-09-08 Impact factor: 2.692
Authors: Leonie N C Visser; Nadine Bol; Marij A Hillen; Mathilde G E Verdam; Hanneke C J M de Haes; Julia C M van Weert; Ellen M A Smets Journal: BMC Med Res Methodol Date: 2018-01-19 Impact factor: 4.615